Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Data
KING OF PRUSSIA, PENNSYLVANIA, March 23, 2026 Phio Pharmaceuticals Corp. has announced the presentation of positive clinical study results...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
KING OF PRUSSIA, PENNSYLVANIA, March 23, 2026 Phio Pharmaceuticals Corp. has announced the presentation of positive clinical study results...
Dateline IntroductionNovember 17, 2025 — Marlborough, Massachusetts — Phio Pharmaceuticals Corp., a clinical-stage biopharmaceutical company advancing RNA-based immuno-oncology therapeutics,...
King of Prussia, Pennsylvania – October 31, 2025 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing...
